Gilde Healthcare
en nl de
  • Portfolio
  • Team
  • Neuigkeiten
  • Über uns
  • Kontakt

Neuigkeiten 2014

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Follow @GildeHealthcare

The 25th treatment center of Fysius Rugexperts is a fact!

18 Dezember 2014 – Press release only available in Dutch: Het 25e behandelcentrum van Fysius Rugexperts is een feit!

Betreffend: Fysius Back Clinics

Pieris Pharmaceuticals, Inc. Goes Public, Raises $12.2 Million

18 Dezember 2014 – Completion of alternative public offering in which Pieris AG becomes a wholly-owned subsidiary of Pieris Pharmaceuticals, Inc. Freising, Germany – Pieris Pharmaceuticals, Inc. (OTC:PIRS) (formerly Marika, Inc.), a Nevada corporation, announced today its successful completion of a…

Betreffend: Pieris Pharmaceuticals Inc.

Preclinical data published on AM-Pharma’s recAP to treat ultra rare disease Hypophosphatasia

2 Dezember 2014 – recAP shown to improve skeletal and dental mineralisation in potentially new indication with high unmet medical need. Bunnik, The Netherlands - AM?Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory…

Betreffend: AM-Pharma

Ascendis Pharma AS Completes $60 Million Oversubscribed Series D Financing

1 Dezember 2014 – Utrecht, The Netherlands and Copenhagen, Denmark - Ascendis Pharma A/S, a biopharmaceutical company that applies its innovative TransCon technology to address significant unmet medical needs, today announced the successful completion of a $60 million Series D financing.  New investors…

Betreffend: Acacia Pharma

Gilde Healthcare portfolio company Definiens acquired by MedImmune

4 November 2014 – Trade sale marks success of portfolio company in Digital Health, an emerging theme in healthcare Utrecht, The Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the transatlantic growth capital firm specialized in the healthcare sector, today announced it has agreed to…

Betreffend: Definiens

Acacia Pharma Announces Positive Phase III Results in Post-Operative Nausea and Vomiting (PONV)

8 Oktober 2014 – Utrecht, the Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the transatlantic growth capital firm specialized in the healthcare sector, announces that its portfolio company Acacia Pharma (Cambridge, UK) announces positive Phase 3 results with APD421 for the management…

Betreffend: Acacia Pharma

Levicept Ltd closes £10 million financing round

7 Oktober 2014 – Sandwich, UK – Levicept Ltd., a biopharmaceutical company focused on the development of LEVI-04, a p75 neurotrophin receptor fusion protein (p75NTR-Fc) for chronic pain indications, announces that it has closed a £10 million Series A financing with Advent Life Sciences, Gilde Healthcare…

Betreffend: Levicept

Gilde Healthcare Portfolio Company ProQR raises $97.5M in bumped up IPO

19 September 2014 – Utrecht, the Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the transatlantic growth capital firm specialized in the healthcare sector, announces that its portfolio company ProQR Therapeutics priced its initial public offering of 7,500,000 ordinary shares at an initial…

Betreffend: ProQR Therapeutics

AM-Pharma Closes €12.2 million Financing Round

11 September 2014 – Bunnik, The Netherlands - AM?Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces that it has closed a €12.2 million financing round led by Gilde Healthcare. Existing investors…

Betreffend: AM-Pharma

Prosonix’ Marketing Authorisation Application for PSX1001 Under Assessment in EU

2 September 2014 – Triggers milestone payment from Mylan OXFORD, UK – Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces that its Marketing Authorisation Application (MAA) for PSX1001 has been validated and is being…

Betreffend: Prosonix

Gilde Healthcare realizes sixth exit in 12 months

26 August 2014 – Sapiens acquired by Medtronic for $200 million in cash Utrecht, The Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the transatlantic growth capital firm specialized in the healthcare sector, today announces it has sold its stake in Sapiens Steering Brain Stimulation…

Betreffend: Sapiens

Sym004 Advances into Two New Clinical Trials and Receives Milestone Payments

7 August 2014 – COPENHAGEN, Denmark 7 - Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that its collaborative partner, Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, Merck Serono has initiated two new clinical studies…

Betreffend: Symphogen

Successful Exit Gilde Healthcare Following Sale of Danish Biopharmaceutical Company Santaris

6 August 2014 – Utrecht (the Netherlands) / Cambridge (USA) — Gilde Healthcare, the transatlantic growth capital firm specialized in the healthcare sector, announces it has sold its minority stake in biopharmaceutical company Santaris Pharma A/S (Copenhagen, Denmark) to Roche (SIX: RO, ROG; OTCQX:…

Betreffend: Santaris Pharma

d3 Medicine LLC and Viroclinics Biosciences BV form virology drug development alliance to serve the

1 Juli 2014 – Strategic alliance to provide services from virology assay development and testing to formulation of accelerated clinical development plans for drugs, biologicals, vaccines and diagnostics Parsippany, New Jersey, United States and Rotterdam, the Netherlands – d3 Medicine LLC, an…

Betreffend: Viroclinics Biosciences

Gilde Healthcare company Definiens closes €15M financing round to expand into digital tissue diagnos

23 Juni 2014 – Definiens AG, a Munich, Germany-based provider of a tissue diagnostics platform aimed at helping physicians improve treatment announced that it has closed a round of financing for € 15 Million. The round was co-led by new investor Wellington Partners and existing investor Gilde Healthcare…

Betreffend: Definiens

Symphogen Relocates to New Headquarters, Names Chief Manufacturing Officer

19 Mai 2014 – New Manufacturing Capabilities to Support early Development Mads Laustsen, formerly of CMC Biologics, Joins Symphogen 1 June 2014 COPENHAGEN, Denmark: Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today announced…

Betreffend: Symphogen

Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients

12 Mai 2014 – SAN DIEGO (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the initiation of a Phase 2b clinical trial of its lead drug candidate, emricasan,…

Betreffend: Conatus Pharmaceuticals

Agendia announces companion diagnostics agreement with Daiichi Sankyo

25 April 2014 – IRVINE, CA and AMSTERDAM – Agendia today announced a new agreement with Daiichi Sankyo regarding oncology drug development and personalized medicine. The agreement calls for Agendia’s oncology biomarker technology to be used in the assessment of novel pharmaceuticals now being researched…

Betreffend: Agendia

Prosonix and Mylan Enter Into Global Licensing Agreement for Generic Versions of Inhaled Respiratory

15 April 2014 – OXFORD, UK, and PITTSBURGH – Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, today announced that it has entered into a global licensing agreement with Mylan Inc. (Nasdaq: MYL), one of the world’s leading…

Betreffend: Prosonix

Gilde Healthcare leads $24 million financing round of respiratory care provider Vapotherm

7 April 2014 – EXETER, New Hampshire - Vapotherm, Inc. announced a $24MM financing round led by Gilde Healthcare. Adage Capital Management joined as new co-investor. The round was completed by existing investors Morgenthaler Ventures, Kaiser Permanente, 3x5 Special Opportunity Fund, Integral Capital…

Betreffend: Vapotherm

Conatus Pharmaceuticals Extends Liver Disease Reach With Phase 2 NAFLD/NASH Trial

3 März 2014 – SAN DIEGO (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the initiation of a Phase 2 clinical trial of its lead drug candidate, emricasan,…

Betreffend: Conatus Pharmaceuticals

Symphogen Enters Clinical cGMP Manufacturing Agreement with Gallus

25 Februar 2014 – Symphogen, A/S, a private biopharmaceutical company developing recombinant monoclonal antibody (mAb) mixtures for the treatment of cancer has signed a manufacturing agreement with Gallus BioPharmaceuticals, LLC (Gallus), a premier pure-play biologics contract manufacturing organization…

Betreffend: Symphogen

uniQure announces successful NASDAQ IPO

6 Februar 2014 – Amsterdam, The Netherlands – uniQure, a Gilde Healthcare portfolio company, announced the pricing of its initial public offering of 5,400,000 ordinary shares at an initial public offering price of $17.00 per ordinary share raising $91.8 million and started trading under the symbol…

Betreffend: uniQure

Definiens Signs Agreement with Clarient to Offer Validated Solutions for Routine Clinical Pathology

3 Februar 2014 – MUNICH - Definiens, the global leader in image analysis for digital pathology and diagnostics announced today the signing of an agreement with Clarient Diagnostic Services, Inc.- which extends the use of Definiens’ automated image analysis software and solutions in Clarient's validated…

Betreffend: Definiens

Conatus Pharmaceuticals Updates Development Strategy and 2014 Milestones

13 Januar 2014 – Leveraging Orphan Drug Designation in Clinical Trial for Liver Transplant Recipients SAN FRANCISCO - (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease,…

Betreffend: Conatus Pharmaceuticals

Gilde Healthcare Services acquires majority share in Viroclinics Biosciences from Erasmus MC

7 Januar 2014 – UTRECHT, THE NETHERLANDS – Gilde Healthcare Services has acquired a majority share in Viroclinics Biosciences (Viroclinics) a virology contract research organization, from Erasmus University Medical Center (Erasmus MC). The partnership between Viroclinics and Gilde Healthcare will…

Betreffend: Viroclinics Biosciences

Gilde Healthcare

Gilde Healthcare

Gilde Healthcare ist ein spezialisierter europäischer Healthcare-Investor und verwaltet über 1,4 Mrd. EUR (1,5 Mrd. USD) in zwei Fondsstrategien: Private Equity sowie Venture & Growth Capital. Der Private Equity-Fonds von Gilde Healthcare investiert in profitable europäische Gesundheitsunternehmen im Mittelstand und konzentriert sich auf die Benelux- und DACH- Region. Der Private-Equity-Fonds richtet sich an Leistungserbringer und Gesundheitsdienstleister sowie Anbieter von Medizinprodukten im Gesundheitswesen. Der Venture & Growth Capital Fonds von Gilde Healthcare investiert in Medizintechnik, digitale Gesundheit und Therapeutika. Die Venture & Growth-Unternehmen sind in Europa und Nordamerika ansässig.

Investment Philosophie

Gilde Healthcare beteiligt sich an schnell wachsenden, innovativen Unternehmen, die bessere Pflege bei niedrigeren Kosten erbringen.

  • Home
  • Portfolio
  • Team
  • Neuigkeiten
  • Kontakt
  • Impressum
  • Privacy Policy
  • SFDR Notifizierung